CD20 therapy, CD22 therapy, and combination therapy with CD19 chimeric antigen receptor (CAR) -expressing cells

摘要

The present invention also relates to methods for the treatment of a subject, for example, by administering to a subject a recombinant T cell comprising CD19 CAR as described herein, in combination with one or more B-cell inhibitors such as CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b , CD179b, or CD79a in combination with at least one of an inhibitor of CD199 or CD79a. The disclosure further features novel antigen binding domains and CAR molecules directed against CD20 and CD22, and for example use as monotherapy or in combination therapy. The present invention also provides the kits and compositions described herein.